This HTML5 document contains 190 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.4212/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q38000242
rdf:type
wikibase:Item
schema:description
scientific article published on May 2010 научни чланак বৈজ্ঞানিক নিবন্ধ artigo científico videnskabelig artikel articolo scientifico vědecký článek wetenschappelijk artikel מאמר מדעי vitskapeleg artikkel scienca artikolo artikull shkencor научная статья наукова стаття, опублікована в травні 2010 vitenskapelig artikkel artículu científicu espublizáu en 2010 vedecký článok wissenschaftlicher Artikel artigo científico article científic artikel ilmiah bilimsel makale artículo científico article scientifique scientific article published on May 2010 artigo científico articol științific مقالة علمية نشرت في مايو 2010 vetenskaplig artikel scientific article published on May 2010
p:P577
wds:Q38000242-D5921321-B30B-4587-B6E6-E90CEDD495D6
wdt:P577
2010-05-01T00:00:00Z
p:P2860
wds:Q38000242-61D9BB91-8898-42D4-9E23-D95D96D76EDC wds:Q38000242-667BFD52-C339-4AF9-B329-743B86DD8DC0 wds:Q38000242-68BEE362-41DF-4C11-8034-FFEC13FC5C06 wds:Q38000242-6BF1CD5A-8CFA-40B5-9628-0CAA43E2172A wds:Q38000242-518C9854-4894-4A04-9F80-32B7A6BED7F9 wds:Q38000242-5227FDEA-A8E1-4E10-9504-DA7E2D3521D0 wds:Q38000242-5ED7817E-C14D-4B7A-A2AA-08C64550AFA5 wds:Q38000242-5EE606E4-86BF-44BA-9569-F009CF8CB1CB wds:Q38000242-3D591C42-0581-4071-802B-196C8FA50A4D wds:Q38000242-42BD3253-62B9-4E2C-8A68-816E08EA7960 wds:Q38000242-2E4C9869-D97F-4FEA-9D08-195436C67BAD wds:Q38000242-307587FC-8BDF-4C71-8E93-5E9D714A1A15 wds:Q38000242-3A9A1D36-C6E6-4220-98AA-5933703C1DB5 wds:Q38000242-3C970064-8881-4BE3-87E0-D801B20EBCAB wds:Q38000242-2D244195-92F1-40FC-AAB3-37A93155008B wds:Q38000242-1CD09456-5330-4809-9213-36137201B35C wds:Q38000242-1F194F52-AD4C-458F-90DC-486E36E15D8E wds:Q38000242-205A5FF1-2F60-4979-82B0-44696AE49130 wds:Q38000242-04852927-E0A7-4F7C-A26E-90200C9CA918 wds:Q38000242-090C72D2-29A3-4F65-899A-7010FA3EC8FA wds:Q38000242-157D3129-ED99-4E2B-AF3A-F77808817C61 wds:Q38000242-00C677A2-EFD5-469E-AE20-404E4100AE3C wds:Q38000242-013AFE3B-E90B-4E3C-8D20-3E8876F77574 wds:Q38000242-02F3E44E-9F1D-46B8-BE81-41CB2984F9DE wds:Q38000242-C6B842CC-EF68-4327-91D7-873398683EAB wds:Q38000242-C86F01C1-1D77-484B-9693-C0D8B630DA7E wds:Q38000242-C9557361-BD50-46AB-A064-46DC94A3197A wds:Q38000242-B81FE224-F5AA-4666-A30C-AA6793D96FFB wds:Q38000242-C4D26D79-4CAA-44DC-A4BC-5F9B3844EDA0 wds:Q38000242-C6327969-7A80-4115-BC32-CB43C90B09E6 wds:Q38000242-B2FAB68F-C852-4B6F-9F7F-92AB95DA89DB wds:Q38000242-B43B83EA-0B8C-4D24-A33D-6A632E7099FE wds:Q38000242-B7B87E0C-8C12-4888-89B4-0C00D58D5302 wds:Q38000242-A080D438-6190-4F7D-AB42-19BD0EF241B1 wds:Q38000242-A0C6B8C2-2964-4DAE-A8CC-E0BC90D27125 wds:Q38000242-A5622969-0E74-4B50-BDA8-FCBD4E92E5BC wds:Q38000242-AC4D75FF-A25B-454D-B28F-3485723604BD wds:Q38000242-904CE01F-820D-4A7E-BDFF-F95F01FA8E47 wds:Q38000242-91534EFE-EE19-4E4E-BABA-1B01350B4D6D wds:Q38000242-9B95259A-C8B8-48E7-A416-F63190366F7A wds:Q38000242-821F3CF6-0F42-4958-AFB8-0E3722DE438F wds:Q38000242-858DE16B-544E-4C31-A067-BD1BA9DBF67D wds:Q38000242-8B52CE90-4225-428E-B738-18EB8BE7479B wds:Q38000242-8C66A339-017E-4C28-A630-7F8407F2FD2D wds:Q38000242-775B4434-DC1A-4C3B-80FC-36AE77BFEFC6 wds:Q38000242-7A1D76E1-779C-4207-8A6F-214AD32CDCD1 wds:Q38000242-7B2BBFD4-850C-4865-8F72-66606F6D6F82 wds:Q38000242-7E3296C4-55CE-42D9-9538-B49BC1132499 wds:Q38000242-6E234744-E8A7-4AC1-90A5-AF3AA078312F wds:Q38000242-709E8C79-9D1D-42EC-8DC7-C317EFABB9D2 wds:Q38000242-76B5E3D2-0F86-47FB-B39A-5F884D922800 wds:Q38000242-FD102776-00B8-4147-B586-4DEE3EA1065A wds:Q38000242-D597E1C7-7677-4922-AE8D-08067640CD1D wds:Q38000242-D705D397-DE3C-4F64-ABFC-3F428647894B wds:Q38000242-E8B8C8E2-1186-4A75-82F9-CFEA12778C04 wds:Q38000242-CA1F97BE-9353-450E-9DFD-AAF8F97B3D07 wds:Q38000242-CB0EDF17-D425-4AC1-A407-68CEF78B8F94
wdt:P2860
wd:Q34991274 wd:Q46114153 wd:Q37190718 wd:Q34155402 wd:Q35675005 wd:Q45127594 wd:Q44991015 wd:Q39536779 wd:Q29547729 wd:Q77522782 wd:Q37179575 wd:Q46607614 wd:Q34426508 wd:Q52561257 wd:Q47957828 wd:Q42212463 wd:Q33982863 wd:Q67858796 wd:Q40913162 wd:Q46929797 wd:Q34910366 wd:Q36263480 wd:Q52081441 wd:Q70212614 wd:Q33979026 wd:Q36856249 wd:Q44897401 wd:Q68344692 wd:Q36538707 wd:Q69752241 wd:Q43882467 wd:Q44453815 wd:Q34983258 wd:Q40290397 wd:Q45302930 wd:Q42613191 wd:Q82635542 wd:Q34509624 wd:Q33982444 wd:Q34965569 wd:Q34755628 wd:Q33746850 wd:Q35123139 wd:Q39743278 wd:Q69510511 wd:Q35253581 wd:Q40802020 wd:Q79429283 wd:Q36328971 wd:Q39487652 wd:Q36554698 wd:Q35952704 wd:Q36677666 wd:Q64135573 wd:Q22241905 wd:Q42608683 wd:Q35826283
p:P2093
wds:Q38000242-037C6D75-C8B8-4037-AE64-6E6E1E7B8E32 wds:Q38000242-D9353F1F-A031-4639-9D20-426D65F648D2 wds:Q38000242-BEE91BF0-553D-41D9-B221-E3CEE41F091B wds:Q38000242-C7FF5485-4CA3-4F8D-A6D8-51CF1C6A084D wds:Q38000242-B391612D-DA23-4ADE-AB16-6C951EA84ABB
wdt:P2093
Lyndsay M van de Vijsel Sandra A N Walker Michelle Hladunewich Sharon Yamashita Scott E Walker
rdfs:label
Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.
skos:prefLabel
Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.
schema:name
Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.
p:P50
wds:Q38000242-3CC61613-5C54-4477-BA16-E0B85E3AF153
wdt:P50
wd:Q106114444
p:P1476
wds:Q38000242-EC52F116-0EDC-4419-98D1-2E168E237B06
wdt:P1476
Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis
p:P304
wds:Q38000242-283E7FAC-EA7E-41E9-AD7D-8B40912A0AB3
wdt:P304
196-206
p:P31
wds:Q38000242-71C2B79D-47A4-4E40-9444-34CCC74EF119
wdt:P31
wd:Q13442814
p:P921
wds:Q38000242-FDD8A610-F7B6-4B1D-AA3E-7DA2214BBA33
wdt:P921
wd:Q424027
p:P698
wds:Q38000242-CBE6F85F-3794-4B6C-83C6-830BB63F2487
wdtn:P698
n6:22478979
wdt:P698
22478979
p:P1433
wds:Q38000242-233DCFAA-FFE2-4A99-B567-0AD0A1D818AB
wdt:P1433
wd:Q15765960
p:P433
wds:Q38000242-4FF43E82-F78B-44B3-B25A-B2AC710AA600
p:P478
wds:Q38000242-9422AD83-B912-4895-BED3-04D2CDD86B04
wdt:P433
3
wdt:P478
63
p:P356
wds:Q38000242-2C379919-252F-47C4-BC9A-A8F65FECE425
wdtn:P356
n11:CJHP.V63I3.915
wdt:P356
10.4212/CJHP.V63I3.915
p:P932
wds:Q38000242-23F77771-8ABD-435E-B957-3B675B0FC360
wdt:P932
2901779